NMTC

NEUROONE MEDICAL TECHNOLOGIES Corp NMTC

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,537 of 2,925

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$1.97M

Quarter to Jun 30

Net income

$-2.01M

Quarter to Jun 30

Free cash flow

$-1.10M

Quarter to Jun 30

Operating margin

-122.9%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$6.18M total
Reading the latest SEC filing…

Key Metrics

Revenue

Q3 2026
EDGAR

Net Income

Q3 2026
EDGAR

EPS (Diluted)

Q3 2026
EDGAR

Operating Margin

Q3 2026
EDGAR

Free Cash Flow

Q3 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/NMTC

Earnings Per Share

13fpro.ai/company/NMTC

Loading ratio trend…

NMTC key financials by period

Reported revenue, net income and operating margin by fiscal year, from NEUROONE MEDICAL TECHNOLOGIES Corp's annual filings on SEC EDGAR.

NEUROONE MEDICAL TECHNOLOGIES Corp reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$9.1M$-3.6M-46.5%
FY 2024$3.5M$-12.3M—
FY 2023$2.0M$-11.9M—
FY 2022$171.2K$-10.0M—
FY 2021$178.1K$-9.9M—
FY 2014$773.00$-36.2K—
Source: NMTC filings on SEC EDGAR →

NMTC insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC): stock profile, AI score and financials

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NMTC at 28.0/100 on a composite quality score built from its SEC filings, placing it at rank #2,537 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q3 2026), NEUROONE MEDICAL TECHNOLOGIES Corp reports quarterly revenue of $2.0M, net income of $-2.0M, an operating margin of -122.9%. Top institutional holders of NMTC by reported 13-F value include Bleichroeder, VANGUARD CAPITAL MANAGEMENT, BARD ASSOCIATES, based on the most recent SEC filings. NMTC trades on the Nasdaq exchange and files with the SEC under CIK 1500198. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NMTC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NEUROONE MEDICAL TECHNOLOGIES Corp directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1500198 →